Cargando…
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels correlated with measures of disease burden were no...
Autores principales: | Putko, Brendan N., Beecher, Grayson, Siddiqi, Zaeem A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477386/ https://www.ncbi.nlm.nih.gov/pubmed/32982936 http://dx.doi.org/10.3389/fneur.2020.00921 |
Ejemplares similares
-
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021) -
Rituximab in refractory myasthenia gravis: a prospective, open‐label study with long‐term follow‐up
por: Anderson, Dustin, et al.
Publicado: (2016) -
Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017) -
Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018) -
Afterdischarges in Myasthenia Gravis
por: Yang, Li, et al.
Publicado: (2021)